What is claimed is:

1. A liquid lansoprazole formulation comprising lansoprazole and an excipient system, wherein:
(a) the concentration of lansoprazole in the formulation ranges from about 0.3 mg/mL to about 50 mg/mL;
(b) the excipient system comprises either a single excipient, or a combination of two to four compositionally distinct excipients, wherein each excipient is selected from the group of excipient categories consisting of: a hydrotrope, a preservative, a pharmaceutically acceptable salt, a surfactant, a base, a cyclodextrin, a viscosity modifier, an emulsifier, a solvent, a carrier, and a lubricant; and
(c) the formulation may be administered parenterally to a mammal in need thereof.

2. A formulation of claim 1, comprising a two-excipient system in which the concentration of each excipient in the formulation ranges from about 0.4 mg/mL to about 60 mg/mL and total excipient concentration in the formulation ranges from about 0.8 mg/mL to about 120 mg/mL.

3. A formulation of claim 2, further comprising a diluent and a preservative that acts as an antimicrobial agent.

4. A formulation of claim 1, comprising lansoprazole and a single excipient.

5. A formulation of claim 1, comprising lansoprazole in combination with a two-excipient system comprising either compositionally distinct first and second excipients selected from the same excipient category, or compositionally distinct first and second excipients selected from different excipient categories.

6. A formulation of claim 4, wherein the excipient is either a hydrotrope, a preservative, a pharmaceutically acceptable salt, a surfactant, a base, a cyclodextrin, a viscosity modifier, an emulsifier, a solvent, a carrier, or a lubricant.

7. A formulation of claim 5, wherein the excipient system comprises either compositionally distinct first and second emulsifiers, or an emulsifier in combination with either: (i) a viscosity modifier, (ii) a carrier, (iii) a base, (iv) a solvent, or (v) a surfactant.

8. A formulation of claim 5, wherein the excipient system comprises a preservative in combination with either: (i) a carrier, (ii) a surfactant, (iii) a solvent, or (iv) a cyclodextrin.

9. A formulation of claim 5, wherein the excipient system comprises either compositionally distinct first and second cyclodextrins, or a cyclodextrin in combination with either: (i) an emulsifier, (ii) a viscosity modifier, (iii) a carrier, (iv) a lubricant, (v) a surfactant, or (vi) a solvent.

10. A formulation of claim 5, wherein the excipient system comprises a pharmaceutically acceptable calcium salt in combination with either: (i) a carrier, (ii) a base, (iii) a solvent, or (iv) a surfactant.

11. A formulation of claim 5, wherein the excipient system comprises either compositionally distinct first and second surfactants, or a surfactant in combination with either: (i) a carrier, (ii) a viscosity modifier, (iii) a base, (iv) a pharmaceutically acceptable salt other than a calcium salt, (v) a solvent, (vi) a lubricant, or (vii) a hydrotrope.

12. A formulation of claim 5, wherein the excipient system comprises a hydrotrope in combination with either: (i) a viscosity modifier, (ii) a carrier, (iii) a preservative, (iv) a base, (v) a solvent, or (vi) a cyclodextrin.

13. A formulation of claim 5, wherein the excipient system comprises either compositionally distinct first and second viscosity modifiers, or a viscosity modifier in combination with either: (i) a carrier, (ii) a lubricant, or (iii) a solvent.

14. A formulation of claim 5, wherein the excipient system comprises either compositionally distinct first and second carriers, or a carrier in combination with either: (i) a solvent, or (ii) a lubricant.

15. A formulation of claim 5, wherein the excipient system comprises either compositionally distinct first and second bases, or a base in combination with either: (i) a preservative, (ii) a solvent, (iii) a carrier, (iv) a viscosity modifier, (v) a lubricant, or (vi) a cyclodextrin.

16. A formulation of claim 5, wherein the excipient system comprises either compositionally distinct first and second solvents, or a solvent in combination with either: (i) a salt, or (ii) a lubricant.

17. A formulation of claim 5, wherein the excipient system comprises compositionally distinct first and second lubricants.

18. A formulation of claim 4, wherein the excipient is selected from the group consisting of: sorbitol, mannitol, lactose, benzethonium chloride, chlorobutanol, methylparaben, methanol, ethanol, i-propanol, n-butanol, calcium chloride, magnesium chloride, calcium gluconate, calcium glubionate, calcium gluceptate, polyoxyethylated castor oil, polysorbate 20, polysorbate 80, poloxamers, deoxycholic acid and salts of deoxycholic acid, lysine, diethanolamine, gamma cyclodextrin, hydroxypropyl-beta-cyclodextrin, polyvinylpyrrolidone, glycerin,

lecithin, sodium benzoate, sodium acetate, sodium tartrate, polyethylene glycol, starch, and propylene glycol.

19. A formulation of claim 5, wherein each excipient is selected from the group consisting of: sorbitol, mannitol, lactose, benzethonium chloride, chlorobutanol, methylparaben, methanol, ethanol, i-propanol, n-butanol, calcium chloride, magnesium chloride, calcium gluconate, calcium glubionate, calcium gluceptate, polyoxyethylated castor oil , polysorbate 20, polysorbate 80, poloxamers, deoxycholic acid and salts of deoxycholic acid, lysine, diethanolamine, gamma cyclodextrin, hydroxypropyl-beta-cyclodextrin, polyvinylpyrrolidone, glycerin, lecithin, sodium benzoate, sodium acetate, sodium tartrate, polyethylene glycol, starch, and propylene glycol.

20. A formulation of claim 1, wherein:

(a) the concentration of lansoprazole in the formulation is between about 4.0 mg/mL to 50 mg/mL; and

(b) the excipient system is a four-excipient system comprising a surfactant, compositionally distinct first and second solvents, and an alcohol.

21. A formulation of claim 20, wherein the surfactant is a polysorbate, the first and second solvents are polyethylene glycols, and the alcohol is methanol, ethanol, i-propanol or n-butanol.

22. A formulation of claim 21, wherein the surfactant is polysorbate 80, the first or second solvent is PEG-300, and the alcohol is ethanol.

23. A formulation of claim 1, wherein:

(a) the concentration of lansoprazole in the formulation is between about 0.4 mg/mL to about 40 mg/mL; and

(b) the excipient system is a three-excipient system comprising a surfactant and compositionally distinct first and second solvents.

24. A formulation of claim 23, wherein the surfactant is a polysorbate and the first and second solvents are compositionally distinct polyethylene glycols.

25. A formulation of claim 24, wherein the surfactant is polysorbate 80 and the first or second solvent is PEG-300.

26. A process of making liquid lansoprazole formulations comprising: dissolving lansoprazole at a concentration of from about 0.3 mg/mL to about 50 mg/mL into an excipient system comprising either a single excipient, or a combination of between two to four compositionally distinct excipients, wherein (a) each excipient is selected from the group of excipient categories consisting of: a hydrotrope, a preservative, a pharmaceutically acceptable salt, a surfactant, a base, a cyclodextrin, a viscosity modifier, an emulsifier, a solvent, a carrier, and a lubricant; and
(b) the formulation may be administered parenterally to a mammal in need thereof.

27. The process of claim 26, comprising dissolving lansoprazole into a single excipient.

28. The process of claim 26, comprising dissolving lansoprazole into a two-excipient system comprising either compositionally distinct first and second excipients selected from the same excipient category, or compositionally distinct first and second excipients selected from different excipient categories.

29. The process of claim 27, wherein the excipient is selected from the group consisting of: sorbitol, mannitol, lactose, benzethonium chloride, chlorobutanol, methylparaben, methanol, ethanol, i-propanol, n-butanol, calcium chloride, magnesium chloride, calcium gluconate, calcium glubionate, calcium gluceptate, polyoxyethylated castor oil, polysorbate 20, polysorbate 80, poloxamers,

deoxycholic acid and salts of deoxycholic acid, lysine, diethanolamine, gamma cyclodextrin, hydroxypropyl-beta-cyclodextrin, polyvinylpyrrolidone, glycerin, lecithin, sodium benzoate, sodium acetate, sodium tartrate, polyethylene glycol, starch, and propylene glycol.

30. The process of claim 28, wherein each excipient is selected from the group consisting of: sorbitol, mannitol, lactose, benzethonium chloride, chlorobutanol, methylparaben, methanol, ethanol, i-propanol, n-butanol, calcium chloride, magnesium chloride, calcium gluconate, calcium glubionate, calcium gluceptate, polyoxyethylated castor oil, polysorbate 20, polysorbate 80, poloxamers, deoxycholic acid and salts of deoxycholic acid, lysine, diethanolamine, gamma cyclodextrin, hydroxypropyl-beta-cyclodextrin, polyvinylpyrrolidone, glycerin, lecithin, sodium benzoate, sodium acetate, sodium tartrate, polyethylene glycol, starch, and propylene glycol.

31. A pharmaceutical dosage form comprising a formulation of claim 4, wherein the formulation may be administered by continuous infusion to a mammal in need thereof.

32. A pharmaceutical dosage form comprising a formulation of claim 5, wherein the formulation may be administered by continuous infusion to a mammal in need thereof.

33. A pharmaceutical dosage form comprising a formulation of claim 4, wherein the formulation may be administered by injection to a mammal in need thereof.

34. A pharmaceutical dosage form comprising a formulation of claim 5, wherein the formulation may be administered by injection to a mammal in need thereof.

35. A method of treating a mammal suffering from a gastrointestinal disorder comprising administering parenterally to the mammal a therapeutically effective amount of a formulation of claim 1.

36. A method of treating a mammal suffering from a gastrointestinal disorder comprising administering parenterally to the mammal a therapeutically effective amount of a formulation of claim 4.

37. A method of treating a mammal suffering from a gastrointestinal disorder comprising administering parenterally to the mammal a therapeutically effective amount of a formulation of claim 5.

38. A method of treating a mammal suffering from a gastrointestinal disorder comprising administering parenterally to the mammal a therapeutically effective amount of a formulation of claim 20.

39. A method of treating a mammal suffering from a gastrointestinal disorder comprising administering parenterally to the mammal a therapeutically effective amount of a formulation of claim 23.

40. The method of claim 35, wherein:
(a) the mammal is a human; and
(b) the formulation of claim 1 has a lansoprazole concentration of about 0.3 mg/mL to 0.4 mg/mL and is administered to the human by continuous infusion over a period of between about ten to twenty minutes.

41. The method of claim 35, wherein:
(a) the mammal is a human; and
(b) the formulation of claim 1 has a lansoprazole concentration of about 3 mg/mL to 4 mg/mL or greater and is administered to the human by injection over a period of about ten minutes or less.

42. A method of treatment comprising administering parenterally to a mammal a prophylactically effective amount of a formulation of claim 1.

43. A method of treatment comprising administering parenterally to a mammal a prophylactically effective amount of a formulation of claim 4.

44. A method of treatment comprising administering parenterally to a mammal a prophylactically effective amount of a formulation of claim 5.

45. A method of treatment comprising administering parenterally to a mammal a prophylactically effective amount of a formulation of claim 20.

46. A method of treatment comprising administering parenterally to a mammal a prophylactically effective amount of a formulation of claim 23.

47. A liquid lansoprazole formulation comprising lansoprazole and an excipient(s) selected from the group consisting of:

(a) lecithin;
(b) lecithin and polyvinylpyrrolidone;
(c) lecithin and sorbitol;
(d) lecithin and lysine;
(e) lecithin and PEG 12;
(f) lecithin and PEG 400;
(g) lecithin and poloxamer 188;
(h) lecithin and polysorbate 80;
(i) lecithin and polysorbate 20;
(j) methylparaben and sorbitol;
(k) methylparaben and polysorbate 80;
(l) methylparaben and polysorbate 20;
(m) gamma-cyclodextrin and lecithin;

(n) gamma-cyclodextrin and polyvinylpyrrolidone;
(o) gamma-cyclodextrin and sorbitol;
(p) gamma-cyclodextrin and sodium acetate;
(q) gamma-cyclodextrin and sodium benzoate;
(r) gamma-cyclodextrin and poloxamer 188;
(s) gamma-cyclodextrin and polysorbate 80;
(t) gamma-cyclodextrin and propylene glycol;
(u) gamma-cyclodextrin and polysorbate 20;
(v) calcium gluceptate and sorbitol;
(w) calcium gluceptate and diethanolamine;
(x) calcium gluceptate and PEG 35 castor oil;
(y) calcium gluceptate and poloxamer 188;
(z) calcium gluceptate and polysorbate 80;
(aa) calcium gluceptate and polysorbate 20;
(bb) deoxycholic acid and lecithin;
(cc) deoxycholic acid and methylparaben;
(dd) deoxycholic acid and gamma-cyclodextrin;
(ee) deoxycholic acid;
(ff) deoxycholic acid and mannitol;
(gg) deoxycholic acid and polyvinylpyrrolidone;
(hh) deoxycholic acid and sorbitol;
(ii) deoxycholic acid and diethanolamine;
(jj) deoxycholic acid and lysine;
(kk) deoxycholic acid and magnesium chloride;
(ll) deoxycholic acid and PEG 12;
(mm) deoxycholic acid and sodium acetate;
(nn) deoxycholic acid and sodium benzoate;
(oo) deoxycholic acid and sodium tartrate;
(pp) deoxycholic acid and ethanol;
(qq) deoxycholic acid and glycerin;
(rr) deoxycholic acid and hydroxypropyl-beta-cyclodextrin;

(ss) deoxycholic acid and PEG 400;
(tt) deoxycholic acid and PEG 6;
(uu) deoxycholic acid and poloxamer 188;
(vv) deoxycholic acid and polysorbate 80;
(ww) deoxycholic acid and propylene glycol;
(xx) deoxycholic acid and polysorbate 20;
(yy) lactose and deoxycholic acid;
(zz) lactose and polyvinylpyrrolidone;
(aaa) lactose and sorbitol;
(bbb) lactose and benzethonium chloride;
(ccc) lactose and diethanolamine;
(ddd) lactose and PEG 35 castor oil;
(eee) lactose and poloxamer 188;
(fff) lactose and polysorbate 80;
(ggg) lactose and polysorbate 20;
(hhh) mannitol and sorbitol;
(iii) mannitol and poloxamer 188;
(jjj) mannitol and polysorbate 80;
(kkk) mannitol and polysorbate 20;
(lll) polyvinylpyrrolidone;
(mmm) polyvinylpyrrolidone and sorbitol;
(nnn) polyvinylpyrrolidone and sodium benzoate;
(ooo) polyvinylpyrrolidone and sodium tartrate;
(ppp) polyvinylpyrrolidone and polysorbate 80;
(qqq) polyvinylpyrrolidone and polysorbate 20;
(rrr) sorbitol;
(sss) sorbitol and polysorbate 80;
(ttt) sorbitol and polysorbate 20;
(uuu) chlorobutanol and sorbitol;
(vvv) chlorobutanol and PEG 35 castor oil;
(www) chlorobutanol and polysorbate 80;

(xxx) benzethonium chloride and calcium gluceptate;

(yyy) benzethonium chloride and chlorobutanol;

(zzz) benzethonium chloride;

(aaaa) benzethonium chloride and PEG 35 castor oil;

(bbbb) benzethonium chloride and polysorbate 80;

(cccc) diethanolamine and lecithin;

(dddd) diethanolamine and gamma-cyclodextrin;

(eeee) diethanolamine and mannitol;

(ffff) diethanolamine and polyvinylpyrrolidone;

(gggg) diethanolamine and sorbitol;

(hhhh) diethanolamine;

(iiii) diethanolamine and lysine;

(jjjj) diethanolamine and sodium acetate;

(kkkk) diethanolamine and ethanol;

(llll) diethanolamine and glycerin;

(mmmm) diethanolamine and hydroxypropyl-beta-cyclodextrin;

(nnnn) diethanolamine and PEG 400;

(oooo) diethanolamine and PEG 6;

(pppp) diethanolamine and poloxamer 188;

(qqqq) diethanolamine and polysorbate 80;

(rrrr) diethanolamine and propylene glycol;

(ssss) diethanolamine and polysorbate 20;

(tttt) lysine and polyvinylpyrrolidone;

(uuuu) lysine and sorbitol;

(vvvv) lysine and poloxamer 188;

(wwww) lysine and polysorbate 80;

(xxxx) lysine and polysorbate 20;

(yyyy) magnesium chloride and sorbitol;

(zzzz) magnesium chloride and poloxamer 188;

(aaaaa) magnesium chloride and polysorbate 80;

(bbbbb) magnesium chloride and polysorbate 20;

(ccccc) PEG 12 and polyvinylpyrrolidone;

(ddddd) PEG 12 and sorbitol;

(eeeee) PEG 12 and poloxamer 188;

(fffff) PEG 12 and polysorbate 80;

(ggggg) PEG 12 and polysorbate 20;

(hhhhh) sodium acetate and sorbitol;

(iiiii) sodium acetate and polysorbate 80;

(jjjjj) sodium acetate and polysorbate 20;

(kkkkk) sodium benzoate and sorbitol;

(lllll) sodium benzoate;

(mmmmm) sodium benzoate and polysorbate 80;

(nnnnn) sodium benzoate and polysorbate 20;

(ooooo) sodium tartrate and sorbitol;

(ppppp) sodium tartrate and polysorbate 80;

(qqqqq) sodium tartrate and polysorbate 20;

(rrrrr) ethanol and sorbitol;

(sssss) ethanol and glycerin;

(ttttt) ethanol and hydroxypropyl-beta-cyclodextrin;

(uuuuu) ethanol and poloxamer 188;

(vvvvv) ethanol and polysorbate 80;

(wwwww) ethanol and propylene glycol;

(xxxxx) ethanol and polysorbate 20;

(yyyyy) glycerin and lecithin;

(zzzzz) glycerin and polyvinylpyrrolidone;

(aaaaaa) glycerin and sorbitol;

(bbbbbb) glycerin and hydroxypropyl-beta-cyclodextrin;

(cccccc) glycerin and poloxamer 188;

(dddddd) glycerin and polysorbate 80;

(eeeeee) glycerin and polysorbate 20;

(ffffff) hydroxypropyl-beta-cyclodextrin and methylparaben;

(gggggg) hydroxypropyl-beta-cyclodextrin and mannitol;

(hhhhhh) hydroxypropyl-beta-cyclodextrin and polyvinylpyrrolidone;
(iiiiii) hydroxypropyl-beta-cyclodextrin and sorbitol;
(jjjjjj) hydroxypropyl-beta-cyclodextrin and PEG 12;
(kkkkkk) hydroxypropyl-beta-cyclodextrin and sodium acetate;
(llllll) hydroxypropyl-beta-cyclodextrin and sodium benzoate;
(mmmmmm) hydroxypropyl-beta-cyclodextrin and sodium tartrate;
(nnnnnn) hydroxypropyl-beta-cyclodextrin and poloxamer 188;
(oooooo) hydroxypropyl-beta-cyclodextrin and polysorbate 80;
(pppppp) hydroxypropyl-beta-cyclodextrin and polysorbate 20;
(qqqqqq) PEG 35 castor oil and lecithin;
(rrrrrr) PEG 35 castor oil and methylparaben;
(ssssss) PEG 35 castor oil and gamma-cyclodextrin;
(tttttt) PEG 35 castor oil and deoxycholic acid;
(uuuuuu) PEG 35 castor oil and mannitol;
(vvvvvv) PEG 35 castor oil and polyvinylpyrrolidone;
(wwwwww) PEG 35 castor oil and sorbitol;
(xxxxxx) PEG 35 castor oil and diethanolamine;
(yyyyyy) PEG 35 castor oil and lysine;
(zzzzzz) PEG 35 castor oil and magnesium chloride;
(aaaaaaa) PEG 35 castor oil and PEG 12;
(bbbbbbb) PEG 35 castor oil and sodium acetate;
(ccccccc) PEG 35 castor oil and sodium benzoate;
(ddddddd) PEG 35 castor oil and sodium tartrate;
(eeeeeee) PEG 35 castor oil and ethanol;
(fffffff) PEG 35 castor oil and glycerin;
(ggggggg) PEG 35 castor oil and hydroxypropyl-beta-cyclodextrin;
(hhhhhhh) PEG 35 castor oil and PEG 400;
(iiiiiii) PEG 35 castor oil and PEG 6;
(jjjjjjj) PEG 35 castor oil and poloxamer 188;
(kkkkkkk) PEG 35 castor oil and polysorbate 80;
(lllllll) PEG 35 castor oil and propylene glycol;

(mmmmmmm) PEG 35 castor oil and polysorbate 20;
(nnnnnnn) PEG 400 and sorbitol;
(ooooooo) PEG 400 and poloxamer 188;
(ppppppp) PEG 400 and polysorbate 80;
(qqqqqqq) PEG 400 and polysorbate 20;
(rrrrrrr) PEG 6 and sorbitol;
(sssssss) PEG 6 and poloxamer 188;
(ttttttt) PEG 6 and polysorbate 80;
(uuuuuuu) PEG 6 and polysorbate 20;
(vvvvvvv) poloxamer 188 and polyvinylpyrrolidone;
(wwwwwww) poloxamer 188 and sorbitol;
(xxxxxxx) poloxamer 188 and sodium acetate;
(yyyyyyy) poloxamer 188 and sodium benzoate;
(zzzzzzz) poloxamer 188 and sodium tartrate;
(aaaaaaaa) poloxamer 188;
(bbbbbbbb) poloxamer 188 and polysorbate 80;
(cccccccc) poloxamer 188 and propylene glycol;
(ddddddddd) poloxamer 188 and polysorbate 20;
(eeeeeeee) polysorbate 80;
(fffffffff) propylene glycol and sorbitol;
(ggggggggg) propylene glycol and polysorbate 80;
(hhhhhhhh) propylene glycol;
(iiiiiiii) propylene glycol and polysorbate 20;
(jjjjjjjj) polysorbate 20 and polysorbate 80;
(kkkkkkkk) polysorbate 20;
(llllllll) lactose and methylparaben;
(mmmmmmmm) mannitol and polyvinylpyrrolidone;
(nnnnnnnn) mannitol and sodium acetate;
(oooooooo) polyvinylpyrrolidone and sodium acetate;
(ppppppppp) chlorobutanol and polysorbate 20;
(qqqqqqqq) benzethonium chloride and lecithin;

(rrrrrrrr) benzethonium chloride and methylparaben;
(ssssssss) benzethonium chloride and gamma-cyclodextrin;
(tttttttt) benzethonium chloride and mannitol;
(uuuuuuuu) benzethonium chloride and polyvinylpyrrolidone;
(vvvvvvvv) benzethonium chloride and sorbitol;
(wwwwwwww) benzethonium chloride and diethanolamine;
(xxxxxxxx) benzethonium chloride and lysine;
(yyyyyyyy) benzethonium chloride and PEG 12;
(zzzzzzzz) benzethonium chloride and sodium acetate;
(aaaaaaaa) benzethonium chloride and sodium tartrate;
(bbbbbbbbb) benzethonium chloride and ethanol;
(ccccccccc) benzethonium chloride and glycerin;
(ddddddddd) benzethonium chloride and hydroxypropyl-beta-cyclodextrin;
(eeeeeeeee) benzethonium chloride and PEG 400;
(fffffffff) benzethonium chloride and PEG 6;
(ggggggggg) benzethonium chloride and poloxamer 188;
(hhhhhhhhh) benzethonium chloride and propylene glycol;
(iiiiiiiii) benzethonium chloride and polysorbate 20;
(jjjjjjjjj) diethanolamine and methylparaben;
(kkkkkkkkk) diethanolamine and magnesium chloride;
(lllllllll) diethanolamine and PEG 12;
(mmmmmmmmm) diethanolamine and sodium benzoate;
(nnnnnnnnn) diethanolamine and sodium tartrate;
(ooooooooo) magnesium chloride and polyvinylpyrrolidone;
(ppppppppp) PEG 12 and sodium acetate;
(qqqqqqqqq) ethanol and lecithin;
(rrrrrrrrr) ethanol and gamma-cyclodextrin;
(sssssssss) ethanol and polyvinylpyrrolidone;
(ttttttttt) ethanol and sodium acetate;
(uuuuuuuuu) hydroxypropyl-beta-cyclodextrin and lysine;

(vvvvvvvvv) hydroxypropyl-beta-cyclodextrin and magnesium chloride;
(wwwwwwwww) hydroxypropyl-beta-cyclodextrin and PEG 400;
(xxxxxxxxx) hydroxypropyl-beta-cyclodextrin and PEG 6;
(yyyyyyyyy) hydroxypropyl-beta-cyclodextrin and propylene glycol;
(zzzzzzzzz) propylene glycol and polyvinylpyrrolidone;
(aaaaaaaaa) lecithin and methylparaben;
(bbbbbbbbb) lecithin and mannitol;
(ccccccccc) lecithin and sodium acetate;
(ddddddddd) lecithin and sodium benzoate;
(eeeeeeeee) lecithin and sodium tartrate;
(fffffffff) lecithin and PEG 6;
(ggggggggg) lecithin and propylene glycol;
(hhhhhhhhh) methylparaben and PEG 12;
(iiiiiiiii) methylparaben and PEG 6;
(jjjjjjjjj) methylparaben and poloxamer 188;
(kkkkkkkkk) gamma-cyclodextrin and methylparaben;
(lllllllll) gamma-cyclodextrin and PEG 12;
(mmmmmmmmm) calcium gluceptate and ethanol;
(nnnnnnnnn) lactose and lecithin;
(ooooooooo) lactose and lysine;
(ppppppppp) lactose and sodium benzoate;
(qqqqqqqqq) lactose and sodium tartrate;
(rrrrrrrrr) lactose and glycerin;
(sssssssss) lactose and PEG 6;
(ttttttttt) mannitol and methylparaben;
(uuuuuuuuu) mannitol and PEG 400;
(vvvvvvvvv) mannitol and propylene glycol;
(wwwwwwwww) chlorobutanol and lecithin;
(xxxxxxxxx) chlorobutanol and diethanolamine;
(yyyyyyyyy) benzethonium chloride and sodium benzoate;
(zzzzzzzzz) lysine and methylparaben;

(aaaaaaaaaaa) lysine and mannitol;

(bbbbbbbbbbb) lysine;

(ccccccccccc) lysine and PEG 6;

(ddddddddddd) magnesium chloride;

(eeeeeeeeeee) magnesium chloride and sodium acetate;

(fffffffffff) magnesium chloride and PEG 400;

(ggggggggggg) sodium tartrate;

(hhhhhhhhhhh) ethanol and methylparaben;

(iiiiiiiiiii) ethanol and mannitol;

(jjjjjjjjjjj) ethanol and sodium benzoate;

(kkkkkkkkkkk) ethanol and PEG 400;

(lllllllllll) ethanol and PEG 6;

(mmmmmmmmmmm) hydroxypropyl-beta-cyclodextrin and lecithin;

(nnnnnnnnnnn) PEG 35 castor oil; and

(ooooooooooo) propylene glycol and sodium acetate.

48. The liquid lansoprazole formulation of claim 47, wherein the excipient(s) comprises a one or a two excipient system.

49. The liquid lansoprazole formulation of claim 47, wherein the concentration of lecithin is:

(a) less than or equal to 0.7 mg/mL;

(b) less than or equal to 0.6 mg/mL;

(c) less than or equal to 0.5 mg/mL;

(d) less than or equal to 0.4 mg/mL;

(e) less than or equal to 0.3 mg/mL;

(f) between about 0.05 and 0.9 mg/mL;

(g) between about 0.1 and 0.8 mg/mL;

(h) between about 0.1 and 0.7 mg/mL;

(i) between about 0.2 and 0.7 mg/mL;

(j) between about 0.3 and 0.6 mg/mL;

(k) about 0.3 mg/mL; or

(l) about 0.6 mg/mL.

50. The liquid lansoprazole formulation of claim 47, wherein the concentration of polyvinylpyrrolidone is:

(a) less than or equal to 25 mg/mL;

(b) less than or equal to 20 mg/mL;

(c) less than or equal to 15 mg/mL;

(d) less than or equal to 12.5 mg/mL;

(e) between about 0.5 and 25 mg/mL;

(f) between about 1 and 25 mg/mL;

(g) between about 2 and 25 mg/mL;

(h) between about 5 and 25 mg/mL;

(i) between about 10 and 25 mg/mL;

(j) between about 10 and 20 mg/mL;

(k) between about 10 and 15 mg/mL;

(l) about 12.5 mg/mL; or

(m) about 25 mg/mL.

51. The liquid lansoprazole formulation of claim 47, wherein the concentration of sorbitol is:

(a) less than or equal to 25 mg/mL;

(b) less than or equal to 20 mg/mL;

(c) less than or equal to 15 mg/mL;

(d) less than or equal to 12.5 mg/mL;

(e) between about 0.5 and 25 mg/mL;

(f) between about 1 and 25 mg/mL;

(g) between about 2 and 25 mg/mL;

(h) between about 5 and 25 mg/mL;

(i) between about 10 and 25 mg/mL;

(j) between about 10 and 20 mg/mL;
(k) between about 10 and 15 mg/mL;
(l) about 12.5 mg/mL; or
(m) about 25 mg/mL.

52. The liquid lansoprazole formulation of claim 47, wherein the concentration of lysine is:

(a) less than or equal to 40 mg/mL;
(b) less than or equal to 35 mg/mL;
(c) less than or equal to 30 mg/mL;
(d) less than or equal to 25 mg/mL;
(e) less than or equal to 20 mg/mL;
(f) between about 0.5 and 40 mg/mL;
(g) between about 1 and 40 mg/mL;
(h) between about 5 and 40 mg/mL;
(i) between about 10 and 40 mg/mL;
(j) between about 15 and 40 mg/mL;
(k) between about 20 and 40 mg/mL;
(l) between about 20 and 30 mg/mL;
(m) about 20 mg/mL; or
(n) about 40 mg/mL.

53. The liquid lansoprazole formulation of claim 47, wherein the concentration of PEG 12 is:

(a) less than or equal to 40 mg/mL;
(b) less than or equal to 35 mg/mL;
(c) less than or equal to 30 mg/mL;
(d) less than or equal to 25 mg/mL;
(e) less than or equal to 20 mg/mL;
(f) between about 0.5 and 40 mg/mL;
(g) between about 1 and 40 mg/mL;

(h) between about 5 and 40 mg/mL;
(i) between about 10 and 40 mg/mL;
(j) between about 15 and 40 mg/mL;
(k) between about 20 and 40 mg/mL;
(l) between about 20 and 30 mg/mL;
(m) about 20 mg/mL; or
(n) about 40 mg/mL.

54. The liquid lansoprazole formulation of claim 47, wherein the concentration of PEG 400 is:

(a) less than or equal to 100 mg/mL;
(b) less than or equal to 75 mg/mL;
(c) less than or equal to 50 mg/mL;
(d) less than or equal to 40 mg/mL;
(e) less than or equal to 25 mg/mL;
(f) between about 0.5 and 100 mg/mL;
(g) between about 1 and 75 mg/mL;
(h) between about 2 and 50 mg/mL;
(i) between about 5 and 50 mg/mL;
(j) between about 10 and 50 mg/mL;
(k) between about 20 and 50 mg/mL;
(l) between about 25 and 50 mg/mL;
(m) about 25 mg/mL; or
(n) about 50 mg/mL.

55. The liquid lansoprazole formulation of claim 47, wherein the concentration of poloxamer 188 is:

(a) less than or equal to 100 mg/mL;
(b) less than or equal to 75 mg/mL;
(c) less than or equal to 50 mg/mL;
(d) less than or equal to 40 mg/mL;

(e) less than or equal to 25 mg/mL;
(f) between about 0.5 and 100 mg/mL;
(g) between about 1 and 75 mg/mL;
(h) between about 2 and 50 mg/mL;
(i) between about 5 and 50 mg/mL;
(j) between about 10 and 50 mg/mL;
(k) between about 20 and 50 mg/mL;
(l) between about 25 and 50 mg/mL;
(m) about 25 mg/mL; or
(n) about 50 mg/mL.

56. The liquid lansoprazole formulation of claim 47, wherein the concentration of polysorbate 80 is:

(a) less than or equal to 100 mg/mL;
(b) less than or equal to 75 mg/mL;
(c) less than or equal to 50 mg/mL;
(d) less than or equal to 40 mg/mL;
(e) less than or equal to 25 mg/mL;
(f) between about 0.5 and 100 mg/mL;
(g) between about 1 and 75 mg/mL;
(h) between about 2 and 50 mg/mL;
(i) between about 5 and 50 mg/mL;
(j) between about 10 and 50 mg/mL;
(k) between about 20 and 50 mg/mL;
(l) between about 25 and 50 mg/mL;
(m) about 25 mg/mL; or
(n) about 50 mg/mL.

57. The liquid lansoprazole formulation of claim 47, wherein the concentration of polysorbate 20 is:

(a) less than or equal to 5 mg/mL;

(b) less than or equal to 4 mg/mL;
(c) less than or equal to 3 mg/mL;
(d) less than or equal to 2 mg/mL;
(e) less than or equal to 1 mg/mL;
(f) less than or equal to 0.5 mg/mL;
(g) between about 0.1 and 5 mg/mL;
(h) between about 0.5 and 5 mg/mL;
(i) between about 1 and 5 mg/mL;
(j) between about 2 and 5 mg/mL;
(k) between about 2.5 and 5 mg/mL;
(l) about 2.5 mg/mL; or
(m) about 5 mg/mL.

58. The liquid lansoprazole formulation of claim 47, wherein the concentration of methylparaben is:

(a) less than or equal to 1 mg/mL;
(b) less than or equal to 0.9 mg/mL;
(c) less than or equal to 0.8 mg/mL;
(d) less than or equal to 0.7 mg/mL;
(e) less than or equal to 0.6 mg/mL;
(f) less than or equal to 0.5 mg/mL;
(g) less than or equal to 0.4 mg/mL;
(h) between about 0.01 and 1 mg/mL;
(i) between about 0.05 and 1 mg/mL;
(j) between about 0.1 and 1 mg/mL;
(k) between about 0.2 and 1 mg/mL;
(l) between about 0.3 and 1 mg/mL;
(m) between about 0.4 and 1 mg/mL;
(n) between about 0.5 and 1 mg/mL;
(o) about 0.5 mg/mL; or
(p) about 1 mg/mL.

59. The liquid lansoprazole formulation of claim 47, wherein the concentration of gamma-cyclodextrin is:

(a) less than or equal to 15 mg/mL;
(b) less than or equal to 12 mg/mL;
(c) less than or equal to 10 mg/mL;
(d) less than or equal to 7.5 mg/mL;
(e) between about 0.1 and 15 mg/mL;
(f) between about 1 and 15 mg/mL;
(g) between about 2.5 and 15 mg/mL;
(h) between about 5 and 15 mg/mL;
(i) between about 7.5 and 15 mg/mL;
(j) between about 7.5 and 12 mg/mL;
(k) between about 7.5 and 10 mg/mL;
(l) about 7 mg/mL; or
(m) about 14 mg/mL.

60. The liquid lansoprazole formulation of claim 47, wherein the concentration of sodium acetate is:

(a) less than or equal to 40 mg/mL;
(b) less than or equal to 35 mg/mL;
(c) less than or equal to 30 mg/mL;
(d) less than or equal to 25 mg/mL;
(e) less than or equal to 20 mg/mL;
(f) between about 0.5 and 40 mg/mL;
(g) between about 1 and 40 mg/mL;
(h) between about 5 and 40 mg/mL;
(i) between about 10 and 40 mg/mL;
(j) between about 15 and 40 mg/mL;
(k) between about 20 and 40 mg/mL;
(l) between about 20 and 30 mg/mL;

(m)about 20 mg/mL; or

(n) about 40 mg/mL.

61. The liquid lansoprazole formulation of claim 47, wherein the concentration of sodium benzoate is:

(a) less than or equal to 40 mg/mL;

(b) less than or equal to 35 mg/mL;

(c) less than or equal to 30 mg/mL;

(d) less than or equal to 25 mg/mL;

(e) less than or equal to 20 mg/mL;

(f) between about 0.5 and 40 mg/mL;

(g) between about 1 and 40 mg/mL;

(h) between about 5 and 40 mg/mL;

(i) between about 10 and 40 mg/mL;

(j) between about 15 and 40 mg/mL;

(k) between about 20 and 40 mg/mL;

(l) between about 20 and 30 mg/mL;

(m)about 20 mg/mL; or

(n) about 40 mg/mL.

62. The liquid lansoprazole formulation of claim 47, wherein the concentration of propylene glycol is:

(a) less than or equal to 100 mg/mL;

(b) less than or equal to 75 mg/mL;

(c) less than or equal to 50 mg/mL;

(d) less than or equal to 40 mg/mL;

(e) less than or equal to 25 mg/mL;

(f) between about 0.5 and 100 mg/mL;

(g) between about 1 and 75 mg/mL;

(h) between about 2 and 50 mg/mL;

(i) between about 5 and 50 mg/mL;

(j) between about 10 and 50 mg/mL;

(k) between about 20 and 50 mg/mL;

(l) between about 25 and 50 mg/mL;

(m) about 25 mg/mL; or

(n) about 50 mg/mL.

63. The liquid lansoprazole formulation of claim 47, wherein the concentration of calcium gluceptate is:

(a) less than or equal to 20 mg/mL;

(b) less than or equal to 17.5 mg/mL;

(c) less than or equal to 15 mg/mL;

(d) less than or equal to 12.5 mg/mL;

(e) less than or equal to 10 mg/mL;

(f) between about 0.1 and 20 mg/mL;

(g) between about 0.5 and 20 mg/mL;

(h) between about 1 and 20 mg/mL;

(i) between about 2.5 and 20 mg/mL;

(j) between about 5 and 20 mg/mL;

(k) between about 7.5 and 20 mg/mL;

(l) between about 10 and 20 mg/mL;

(m) between about 10 and 15 mg/mL;

(n) about 10 mg/mL; or

(o) about 20 mg/mL.

64. The liquid lansoprazole formulation of claim 47, wherein the concentration of diethanolamine is:

(a) less than or equal to 40 mg/mL;

(b) less than or equal to 35 mg/mL;

(c) less than or equal to 30 mg/mL;

(d) less than or equal to 25 mg/mL;

(e) less than or equal to 20 mg/mL;

(f) between about 0.5 and 40 mg/mL;
(g) between about 1 and 40 mg/mL;
(h) between about 5 and 40 mg/mL;
(i) between about 10 and 40 mg/mL;
(j) between about 15 and 40 mg/mL;
(k) between about 20 and 40 mg/mL;
(l) between about 20 and 30 mg/mL;
(m) about 20 mg/mL; or
(n) about 40 mg/mL.

65. The liquid lansoprazole formulation of claim 47, wherein the concentration of PEG 35 castor oil is:

(a) less than or equal to 100 mg/mL;
(b) less than or equal to 75 mg/mL;
(c) less than or equal to 50 mg/mL;
(d) less than or equal to 40 mg/mL;
(e) less than or equal to 25 mg/mL;
(f) between about 0.5 and 100 mg/mL;
(g) between about 1 and 75 mg/mL;
(h) between about 2 and 50 mg/mL;
(i) between about 5 and 50 mg/mL;
(j) between about 10 and 50 mg/mL;
(k) between about 20 and 50 mg/mL;
(l) between about 25 and 50 mg/mL;
(m) about 25 mg/mL; or
(n) about 50 mg/mL.

66. The liquid lansoprazole formulation of claim 47, wherein the concentration of deoxycholic acid is:

(a) less than or equal to 25 mg/mL;
(b) less than or equal to 20 mg/mL;

(c) less than or equal to 15 mg/mL;
(d) less than or equal to 12.5 mg/mL;
(e) between about 0.5 and 25 mg/mL;
(f) between about 1 and 25 mg/mL;
(g) between about 2 and 25 mg/mL;
(h) between about 5 and 25 mg/mL;
(i) between about 10 and 25 mg/mL;
(j) between about 10 and 20 mg/mL;
(k) between about 10 and 15 mg/mL;
(l) about 12.5 mg/mL; or
(m) about 25 mg/mL.

67. The liquid lansoprazole formulation of claim 47, wherein the concentration of mannitol is:

(a) less than or equal to 25 mg/mL;
(b) less than or equal to 20 mg/mL;
(c) less than or equal to 15 mg/mL;
(d) less than or equal to 12.5 mg/mL;
(e) between about 0.5 and 25 mg/mL;
(f) between about 1 and 25 mg/mL;
(g) between about 2 and 25 mg/mL;
(h) between about 5 and 25 mg/mL;
(i) between about 10 and 25 mg/mL;
(j) between about 10 and 20 mg/mL;
(k) between about 10 and 15 mg/mL;
(l) about 12.5 mg/mL; or
(m) about 25 mg/mL.

68. The liquid lansoprazole formulation of claim 47, wherein the concentration of magnesium chloride is:

(a) less than or equal to 40 mg/mL;

(b) less than or equal to 35 mg/mL;

(c) less than or equal to 30 mg/mL;

(d) less than or equal to 25 mg/mL;

(e) less than or equal to 20 mg/mL;

(f) between about 0.5 and 40 mg/mL;

(g) between about 1 and 40 mg/mL;

(h) between about 5 and 40 mg/mL;

(i) between about 10 and 40 mg/mL;

(j) between about 15 and 40 mg/mL;

(k) between about 20 and 40 mg/mL;

(l) between about 20 and 30 mg/mL;

(m)about 20 mg/mL; or

(n) about 40 mg/mL.

69. The liquid lansoprazole formulation of claim 47, wherein the concentration of sodium tartrate is:

(a) less than or equal to 40 mg/mL;

(b) less than or equal to 35 mg/mL;

(c) less than or equal to 30 mg/mL;

(d) less than or equal to 25 mg/mL;

(e) less than or equal to 20 mg/mL;

(f) between about 0.5 and 40 mg/mL;

(g) between about 1 and 40 mg/mL;

(h) between about 5 and 40 mg/mL;

(i) between about 10 and 40 mg/mL;

(j) between about 15 and 40 mg/mL;

(k) between about 20 and 40 mg/mL;

(l) between about 20 and 30 mg/mL;

(m)about 20 mg/mL; or

(n) about 40 mg/mL.

70. The liquid lansoprazole formulation of claim 47, wherein the concentration of ethanol is:

(a) less than or equal to 100 mg/mL;
(b) less than or equal to 75 mg/mL;
(c) less than or equal to 50 mg/mL;
(d) less than or equal to 40 mg/mL;
(e) less than or equal to 25 mg/mL;
(f) between about 0.5 and 100 mg/mL;
(g) between about 1 and 75 mg/mL;
(h) between about 2 and 50 mg/mL;
(i) between about 5 and 50 mg/mL;
(j) between about 10 and 50 mg/mL;
(k) between about 20 and 50 mg/mL;
(l) between about 25 and 50 mg/mL;
(m) about 25 mg/mL; or
(n) about 50 mg/mL.

71. The liquid lansoprazole formulation of claim 47, wherein the concentration of glycerin is:

(a) less than or equal to 100 mg/mL;
(b) less than or equal to 75 mg/mL;
(c) less than or equal to 50 mg/mL;
(d) less than or equal to 40 mg/mL;
(e) less than or equal to 25 mg/mL;
(f) between about 0.5 and 100 mg/mL;
(g) between about 1 and 75 mg/mL;
(h) between about 2 and 50 mg/mL;
(i) between about 5 and 50 mg/mL;
(j) between about 10 and 50 mg/mL;
(k) between about 20 and 50 mg/mL;
(l) between about 25 and 50 mg/mL;

(m)about 25 mg/mL; or

(n) about 50 mg/mL.

72. The liquid lansoprazole formulation of claim 47, wherein the concentration of hydroxypropyl-beta-cyclodextrin is:

(a) less than or equal to 100 mg/mL;

(b) less than or equal to 75 mg/mL;

(c) less than or equal to 50 mg/mL;

(d) less than or equal to 40 mg/mL;

(e) less than or equal to 25 mg/mL;

(f) between about 0.5 and 100 mg/mL;

(g) between about 1 and 75 mg/mL;

(h) between about 2 and 50 mg/mL;

(i) between about 5 and 50 mg/mL;

(j) between about 10 and 50 mg/mL;

(k) between about 20 and 50 mg/mL;

(l) between about 25 and 50 mg/mL;

(m)about 25 mg/mL; or

(n) about 50 mg/mL.

73. The liquid lansoprazole formulation of claim 47, wherein the concentration of PEG 6 is:

(a) less than or equal to 100 mg/mL;

(b) less than or equal to 75 mg/mL;

(c) less than or equal to 50 mg/mL;

(d) less than or equal to 40 mg/mL;

(e) less than or equal to 25 mg/mL;

(f) between about 0.5 and 100 mg/mL;

(g) between about 1 and 75 mg/mL;

(h) between about 2 and 50 mg/mL;

(i) between about 5 and 50 mg/mL;

(j) between about 10 and 50 mg/mL;

(k) between about 20 and 50 mg/mL;

(l) between about 25 and 50 mg/mL;

(m)about 25 mg/mL; or

(n) about 50 mg/mL.

74. The liquid lansoprazole formulation of claim 47, wherein the concentration of lactose is:

(a) less than or equal to 25 mg/mL;

(b) less than or equal to 20 mg/mL;

(c) less than or equal to 15 mg/mL;

(d) less than or equal to 12.5 mg/mL;

(e) between about 0.5 and 25 mg/mL;

(f) between about 1 and 25 mg/mL;

(g) between about 2 and 25 mg/mL;

(h) between about 5 and 25 mg/mL;

(i) between about 10 and 25 mg/mL;

(j) between about 10 and 20 mg/mL;

(k) between about 10 and 15 mg/mL;

(l) about 12.5 mg/mL; or

(m)about 25 mg/mL.

75. The liquid lansoprazole formulation of claim 47, wherein the concentration of benzethonium chloride is:

(a) less than or equal to 40 mg/mL;

(b) less than or equal to 35 mg/mL;

(c) less than or equal to 30 mg/mL;

(d) less than or equal to 25 mg/mL;

(e) less than or equal to 20 mg/mL;

(f) between about 0.5 and 40 mg/mL;

(g) between about 1 and 40 mg/mL;

(h) between about 5 and 40 mg/mL;
(i) between about 10 and 40 mg/mL;
(j) between about 15 and 40 mg/mL;
(k) between about 20 and 40 mg/mL;
(l) between about 20 and 30 mg/mL;
(m) about 20 mg/mL; or
(n) about 40 mg/mL.

76. The liquid lansoprazole formulation of claim 47, wherein the concentration of chlorobutanol is:

(a) less than or equal to 3 mg/mL;
(b) less than or equal to 2.5 mg/mL;
(c) less than or equal to 2 mg/mL;
(d) less than or equal to 1.5 mg/mL;
(e) between about 0.01 and 3 mg/mL;
(f) between about 0.05 and 3 mg/mL;
(g) between about 0.1 and 3 mg/mL;
(h) between about 0.5 and 3 mg/mL;
(i) between about 1 and 3 mg/mL;
(j) between about 1.5 and 3 mg/mL;
(k) between about 1.5 and 2.5 mg/mL;
(l) about 1.5 mg/mL; or
(m) about 3 mg/mL.

77. The liquid lansoprazole formulation of claim 47, wherein the lansoprazole concentration is:

(a) greater than or equal to about 0.3 mg/mL;
(b) greater than or equal to about 0.4 mg/mL;
(c) greater than or equal to about 0.5 mg/mL;
(d) greater than or equal to about 0.6 mg/mL;
(e) greater than or equal to about 0.7 mg/mL;

(f) greater than or equal to about 0.8 mg/mL;
(g) greater than or equal to about 0.9 mg/mL;
(h) greater than or equal to about 1.0 mg/mL;
(i) greater than or equal to about 2 mg/mL;
(j) greater than or equal to about 3 mg/mL;
(k) greater than or equal to about 4 mg/mL;
(l) greater than or equal to about 5 mg/mL;
(m) greater than or equal to about 10 mg/mL;
(n) greater than or equal to about 20 mg/mL;
(o) greater than or equal to about 30 mg/mL;
(p) greater than or equal to about 40 mg/mL;
(q) between about 0.3 and 40 mg/mL;
(r) between about 0.3 and 30 mg/mL;
(s) between about 0.3 and 20 mg/mL;
(t) between about 0.3 and 10 mg/mL;
(u) between about 0.3 and 5 mg/mL;
(v) about 0.3 mg/mL;
(w) about 0.4 mg/mL;
(x) about 0.5 mg/mL;
(y) about 0.7 mg/mL;
(z) about 1 mg/mL;
(aa) about 2 mg/mL;
(bb) about 3 mg/mL;
(cc) about 4 mg/mL; or
(dd) about 5 mg/mL.

78. A liquid lansoprazole formulation comprising lansoprazole and a two, three, or four excipient system, wherein the excipients comprise:

(a) polysorbate 80 and PEG 400;
(b) polysorbate 80 and polypropylene glycol;
(c) polysorbate 80 and ethanol;

(d) PEG 300 and polypropylene glycol;
(e) polysorbate 20 and PEG 300;
(f) polypropylene glycol and ethanol;
(g) polysorbate 80 and PEG 300;
(h) PEG 300 and ethanol;
(i) polypropylene glycol, PEG 300, and ethanol;
(j) polysorbate 80, PEG 300, and ethanol
(k) polysorbate 80, polypropylene glycol, and ethanol;
(l) polysorbate 80, polypropylene glycol, and PEG 300; or
(m) polysorbate 80, polypropylene glycol, PEG 300, and ethanol.

79. The liquid lansoprazole formulation of claim 78, wherein the lansoprazole concentration is:

(a) less than or equal to about 35 mg/mL;
(b) less than or equal to about 30 mg/mL;
(c) less than or equal to about 25mg/mL;
(d) less than or equal to about 20 mg/mL;
(e) less than or equal to about 15 mg/mL;
(f) less than or equal to about 10 mg/mL;
(g) less than or equal to about 5 mg/mL;
(h) less than or equal to about 4 mg/mL;
(i) less than or equal to about 1 mg/mL;
(j) less than or equal to about 0.4 mg/mL;
(k) between about 0.4 and 35 mg/mL;
(l) between about 1 and 35 mg/mL;
(m) between about 4 and 35 mg/mL;
(n) between about 5 and 35 mg/mL;
(o) between about 10 and 35 mg/mL;
(p) between about 15 and 35 mg/mL;
(q) between about 20 and 35 mg/mL;
(r) between about 25 and 35 mg/mL;

(s) about 20 mg/mL;
(t) about 25 mg/mL;
(u) about 30 mg/mL; or
(v) about 35 mg/mL.

80. The liquid lansoprazole formulation of claim 78, wherein the lansoprazole concentration is:

(a) greater than or equal to 25 mg/mL;
(b) greater than or equal to 30 mg/mL;
(c) greater than or equal to 35 mg/mL;
(d) greater than or equal to 40 mg/mL;
(e) greater than or equal to 45 mg/mL;
(f) between about 25 and 45 mg/mL;
(g) between about 30 and 45 mg/mL;
(h) between about 35 and 45 mg/mL;
(i) between about 40 and 45 mg/mL;
(j) between about 35 and 40 mg/mL;
(k) about 30 mg/mL;
(l) about 35 mg/mL;
(m) about 40 mg/mL; or
(n) about 45 mg/mL.

81. The liquid lansoprazole formulation of claim 78, wherein the ratio of excipients in a two excipient system is:

(a) 1:1;
(b) 2:1;
(c) 1.5:1;
(d) 1:2;
(e) 1:1.5;
(f) 1:3; or
(g) 3:1.

82. The liquid lansoprazole formulation of claim 78, wherein the ratio of excipients in a three excipient system is:

(a) 0.3:0.8:0.2;

(b) 1:1:1;

(c) 2:1:1;

(d) 2:1:0.5; or

(e) 2.5:1.0:0.5.

83. The liquid lansoprazole formulation of claim 78, wherein the ratio of excipients in a four excipient system is:

(a) 2.0:1.0:0.8:0.2;

(b) 1:1:1:1;

(c) 2:1:1:1;

(d) 2:1:2:1; or

(e) 2:1:1:0.5.

84. A liquid pharmaceutical formulation suitable for parenteral administration to a mammal comprising:

(a) lansoprazole, a derivative, or a pharmaceutically acceptable salt thereof; and

(b) one or more of an oil, a solvent, a surfactant or another excipient.